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Introduction
Solitary fibrous tumor (SFT) is a rare soft tissue tumor 
of mesenchymal origin. Originally described in pleural 
tumors by Klemperer and Rabin in 1931, these tumors have 
represented a unique diagnostic and treatment challenge (1). 
With gross and histologic features that overlap with many 
other soft tissue tumors, SFT have been assigned many 
different names in the past including benign mesothelioma, 
localized mesothelioma, solitary fibrous mesothelioma, 
and localized fibrous tumor to name a few. A prime 
example is the paper from Stout and Murray published 
only a decade after Klemperer and Rabin which described 
the histologic features of SFT but assigned the name 
hemangiopericytoma (2). More recently the discovery 
of the SFT fusion gene has led to the abandonment of 
the term hemangiopericytoma in favor of SFT. Due to 
the low incidence of SFT the majority of data has been 
derived from small retrospective series and case reports 
which has made developing specific diagnostic strategies 
and treatment planning difficult. Over the years, however, 
continued discovery and pooled research has led to further 
differentiation of hundreds of soft tissue masses including 
SFT. Furthermore advances in histologic, molecular and 
genetic techniques have allowed more precise categorization 
and identification of soft tissue tumors.
Epidemiology
While the etiology of SFT is currently unknown, data 
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supports these tumors arise from cells of mesenchymal 
origin (3-5). It has an equal distribution between men and 
women (6,7). SFTs may be diagnosed in adults of all ages, 
with most commonly presenting in the 5th and 6th decade 
(6-8). To date there are no environmental factors identified 
that increase the risk of SFT. 
Clinical presentation
SFT tumors may be found in almost any site of the body 
with intra-thoracic being the most common location 
followed by intra-abdominal (6,9,10). Figure 1 shows 
a detailed break down of tumor locations. Within the 
thoracic cavity the majority are pleural-based followed 
by lung parenchymal tumors, then the mediastinum and 
the diaphragm (6). They arise equally in the right and left 
chest (11). SFT in the mediastinum have a propensity to arise 
in the anterior mediastinum (12). The majority, between 
50–80%, of thoracic SFT will present as asymptomatic 
masses discovered incidentally on chest imaging (6,11,13). 
Those that do present with symptoms present with 
nonspecific chest complaints such as chest pain, dyspnea or 
cough (6,11,12,14).
The most common extrapleural site and second most 
common location overall is the abdomen (6). These have 
been noted to be in intra-peritoneal, retroperitoneal, and 
pelvic locations (6,9,10,15). Intra-abdominal SFT are 
generally asymptomatic until they reach large enough size 
to cause mass effect on other organs.
Less common locations include the trunk, extremities, 
head and neck, and intracranial (6,9,16,17). Those arising 
in the head and neck may arise from the sinonasal tract, oral 
cavity or the orbit (18-21). Intracranial SFT arise from the 
meninges (17). Tumors in these locations typically present 
with localized symptoms. 
On rare occasions SFT can present with paraneoplastic 
syndromes, the most commonly described being non-islet 
cell hypoglycemia (5,22). This is due to tumor production 
Figure 1 Solitary fibrous tumor involving the prostate with benign features. (A) Low power view with fascicular pattern and occasional large, 
sometimes branching blood vessels; (B) high power view showing oval to spindle-shaped nuclei and cells with focally fascicular pattern; 
(C) CD34 immunohistochemical stain with cytoplasmic staining; (D) STAT6 immunohistochemical staining with nuclear staining. H&E 
staining; A: ×100; B,C,D: ×200.
A B
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of high molecular weight insulin-like growth factor (IGF), 
specifically IGF-II (22). Seventy percent of these tumors will 
exhibit malignant behavior and presence of non-islet cell 
hypoglycemia is an overall poor prognostic indicator (22).
Tumor size at presentation is highly variable and is 
typically associated with location. The median size among 
several studies is noted between 7–10 cm with a range 
from anywhere from 1 to 40 cm (6,7,12,16). Grossly, 
these tumors are typically well circumscribed with smooth 
surfaces and many times a lobulated shape (6,7). 
Work up/diagnosis
The work up and diagnosis of SFT is analogous to many 
other soft tissue masses. Because many are asymptomatic 
or have non-specific symptoms, they are often found 
incidentally on imaging. Plain chest radiographs typically 
show a well-defined mass of variable size originating 
from the pleura with or without a pedicle (23). Contrast 
enhanced computed tomography (CT) will demonstrate a 
well-circumscribed, often lobulated, hypervascular tumor 
often with areas of necrosis especially when large (4,24,25). 
T2-weighted magnetic resonance imaging (MRI) typically 
reveal a well-defined mass that is markedly inhomogeneous 
with large areas of bright signaling reflecting extensive areas 
of necrosis (4,23). 
A pre-treatment biopsy to diagnose and grade the mass 
is ideal. This biopsy should be performed by an individual 
experienced in soft tissue mass biopsy techniques. Open 
incisional biopsy by an experienced surgeon or, alternatively, 
core needle biopsy is preferred. Repeat biopsy can be 
considered if the initial biopsy is inadequate or fails to make 
the diagnosis. Depending on location, radiologic guided 
biopsy may prove to be helpful (26). The differential is 
typically vast and SFT is usually not high on this differential 
given the relative rarity. Classically, SFTs are composed of 
spindle to ovoid cells arranged in patternless distribution 
with areas of tumor cells and other hypocellular regions 
with higher percentage of stromal collagen (6,15,27). 
Molecular genetic analysis has proven vital in further 
differentiating soft tissue masses for diagnosis. SFT has 
recently been associated with a NAB2-STAT6 gene fusion 
product that has proven to be highly specific and sensitive 
for SFT (28). This discovery of this gene fusion product has 
been pivotal for their diagnosis. However, the differential 
of a soft tissue mass with STAT6 expression should also 
include dedifferentiated liposarcoma (29). Further analysis 
and confirmation of positivity for MDM2 and CKD4 
can help differentiate the two and confirm a diagnosis of 
dedifferentiated liposarcoma (15,30,31). Given the broad 
differential and genetic overlap in many of these tumors, 
work-up and management should be determined in a 
multidisciplinary setting, where personalized aspects of each 
individual case can be discussed and taken into account.
Histopathology
SFTs are variably cellular and composed of cells with 
oval to spindle-shaped nuclei with minimal cytoplasm 
and intervening collagen bands arranged in patternless 
distribution with areas highly rich in tumor cells while 
other areas are more hypocellular with higher percentage 
of stromal collagen (Figures 1A,B,2A) (6,7,11,15,27). 
Nuclear atypia is usually minimal and mitotic figures are 
few in number, although exceptions occur (6,7,11,15,27). 
Smaller tumors tend to be poorly vascularized with fewer 
mitoses and uniformed, elongated spindle cells and variable 
amounts of collagen versus larger tumors that have more 
pleomorphism and higher mitotic counts (Figure 2B,C) (4). 
Many cases may display a hemangiopericytic growth pattern 
due to pronounced vascularity, known as “staghorn” blood 
vessels, and perivascular sclerosis (4,6,7,11,15,27). 
Several unusual features that may suggest different 
diagnoses are occasionally seen and it should be recognized 
that these appearances do not exclude SFT. Fat production 
is seen in approximately 8% of tumors (32). Focal or 
extensive myxoid change or multinucleated giant cells also 
may be observed (33,34). 
CD34 has been noted to be one of the most consistent 
conventional markers in SFT and previously was the 
primary immunohistochemical (IHC) marker with 
expression in 79% of cases (Figure 1C) (35). Its lack of 
specificity, however, can occasionally be problematic 
(6,7,21). Gastrointestinal stomal tumor, another CD34 
positive stromal tumor that may occur in unexpected sites 
such as the retroperitoneum, should always be excluded 
through appropriate IHC staining for CD117/(c-KIT) and 
DOG1 (36). Many other markers are variably expressed in 
SFT such as vimentin, CD99, BCL2, nuclear β-catenin, and 
epithelial membrane antigen (EMA) (6,15,16,37-39). 
Strong nuclear STAT6 IHC staining has been used to 
reliably differentiate SFT from other soft tissue tumors, 
tumors of the head and neck, gynecologic tract and prostate 
(Figures 1D,2D) (40-43). In a recent review of 231 soft 
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tissue tumors by Doyle et al., 59 of 60 (98%) cases of SFT 
showed nuclear staining for STAT6 while all other tumor 
types were negative for STAT6 with the exception of 3 
dedifferentiated liposarcomas (15). It should be noted that 
only strong, diffuse nuclear staining is highly specific for 
SFT, as weak staining can be seen in some other tumors. 
Recently, multiple groups discovered a gene fusion 
product between NAB2 and STAT6, which is a highly 
sensitive and specific marker for SFT and is considered 
the molecular hallmark of SFT. The STAT6-NAB2 
fusion product results from an inversion at the 12q13 
locus inducing expression of early growth response 
(EGR) mediated pathways (15). These fusions have been 
demonstrated by polymerase chain reaction to be present 
in 91% of SFT, with absence of this function in potentially 
histologically similar appearing tumors (44). This fusion 
may also be detected by a break-apart fluorescent in situ 
hybridization probe, seen in 58% of cases in one study (45). 
This did not, however, correlate with patient outcome. 
Telomerase reverse transcriptase (TERT) promoter mutations 
have been seen in 28% of SFT and are associated with high 
risk pathologic characteristics and outcomes (46). 
Staging
The 2013 World Health Organization classification of soft 
tissue sarcomas helped further differentiate many sarcomas 
with SFT being classified as a fibroblastic/myofibroblastic 
tumor (47). The American Joint Committee on Cancer 
(AJCC) staging system is the most commonly used staging 
system for soft tissue sarcomas. There are separate staging 
criteria depending on the location of each tumor which 
includes head and neck, trunk and extremities, abdomen and 
thoracic visceral organs, and retroperitoneum. Their system 
takes into account characteristics of the primary tumor (T), 
lymph nodes (N), distant metastasis (M) and grade (G) (48). 
The grade is determined by tumor differentiation, mitotic 
count and tumor necrosis (26).
Figure 2 Solitary fibrous tumor of the pelvis of a male patient with malignant features. (A) Low power view with frequent, sometimes 
branching blood vessels; (B) high power view with nuclear enlargement and pleomorphism and coagulative tumor necrosis; (C) high power 
view showing overtly malignant nuclear features and frequent mitoses; (D) STAT6 immunohistochemical stain with nuclear staining. H&E 
staining; A: ×100; B,C,D: ×200.
A B
C D
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Treatment
Due to the paucity of randomized control trials there is no 
established, globally accepted treatment strategy. As a result, 
SFT should be approached in a manner similar to other 
soft tissue sarcomas, by a multidisciplinary team consisting 
of surgeons, medical oncologists, radiation oncologists, 
and additional ancillary support. This strategy has proven 
to improve outcomes in soft tissue sarcomas (49-52). For a 
more in depth overview on sarcoma management please see 
the article by Milgrom et al. in this special issue (53).
Surgery
Surgical management has been the mainstay treatment 
for SFTs (4,6,7,11,13). Given the variable location of the 
primary tumor, surgical planning and intervention is highly 
variable based upon location and involved structures. 
Surgical management of SFTs is similar to most soft 
tissue sarcomas with a goal of wide resection margins and 
preservation of any critical surrounding organs or other 
structures. Obtaining adequate negative margins has been 
shown to decrease the rate local disease recurrence and 
improve survival (54). Several case series have demonstrated 
complete resection to be associated with low rates of local 
recurrence and progression to metastatic disease (4,9-13,55). 
Long-term follow up in small case series have demonstrated 
local recurrence as low as 8% after complete resection, 
however, true recurrence rates may be higher as recurrence 
has been reported to occur as far out as 17 years following 
resection (4,56). Malignant SFT tumors, however, like other 
STS have a less durable response with up to 63% recurring 
even after complete resection (4). Thus, in instances of 
positive surgical margins, particularly in higher-grade SFT, 
surgical re-resection should be considered (4,26). 
Radiation therapy 
The use of radiation therapy in treatment of SFTs is 
unfortunately limited by lack of data given the rarity of this 
tumor. Given the relatively good outcomes and indolent 
nature of this tumor, radiation therapy is not currently 
recommended after complete resection with negative 
margins. The indications and effectiveness of adjuvant 
radiation with positive margins or recurrent tumors has 
been debated but here too the benefit of radiation therapy 
remains undetermined. The role of adjuvant radiation has 
been most greatly studied in the CNS population (57). In an 
analysis of 155 patients with central nervous system SFTs, 
overall survival was noted to be higher (93% vs. 88%) with 
surgery and radiation when compared to surgery alone, 
however this was not statistically significant (P=0.78) (57). 
This marginal potential benefit, however, has been 
corroborated in additional studies on intra-cranial SFT 
suggesting improved responses and outcomes with radiation 
therapy for patients with incomplete resection or metastatic 
disease (58,59). 
Although the role of adjuvant radiation for non-
intracranial tumors is still unclear, small case series have 
suggested potential encouraging results. Kawamura et al. 
demonstrated a good response to radiation therapy in a 
74-year old female with metastatic SFT of the pelvis (60). 
Saynak et al. have published their experience of treating a 
66-year old patient with pleural SFT with radiation and 
achieving a significant response (61). Experiences such as 
these show the potential promise of radiation therapy for 
SFT, and support its consideration in a case-by-case basis 
likely as part of a multidisciplinary plan. 
Chemotherapy
The relatively low incidence of SFTs has made it difficult to 
identify the most effective chemotherapy for advanced SFT. 
Further much of the data has been studied in a retrospective 
fashion. There have been multiple retrospective studies 
evaluating the effectiveness of standard cytotoxic chemotherapy 
with doxorubicin-based regimens. Results have been variable, 
but most have shown low or questionable response rates 
(62,63). A study from the oncology group at Centre Leon 
Berard evaluated 23 patients who received first line cytotoxic 
chemotherapy. Only 2 partial responses were observed, 
13 patients had stable disease and the remaining 8 patients’ 
disease had progressed at 6 months (62). Because of these 
low response rates, more research has started looking into 
targeted therapies. In a retrospective analysis of 11 patients, 
combination therapy with temozolomide and bevacizumab was 
shown to have a partial response in 79%, stable disease in 14%, 
and progressive disease in 7% (64). Additional research has 
looked into the sensitivity of multiple antiangiogenics including 
pazopanib, sorafenib, sunitinib, regorafenib, and axitinib (65). 
Sunitinib has been further studied and showed activity against 
SFT (66,67). In a series of 31 patients, a partial response was 
seen in 2 patients, stabilization in 16 patients, and progression 
in 13 (66). As effectiveness of these chemotherapies is still 
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relatively poor, additional clinical studies are needed to better 
elucidate the molecular pathways involved with SFT in order 
to treat it more effectively.
Prognosis
While the behavior of most tumors is benign but potentially 
locally aggressive, a significant fraction of patients will have 
tumors that demonstrate malignant behavior. The biologic 
behavior of individual SFTs is hard to predict, and even 
tumors considered histologically benign may aggressively 
recur (68,69). Nonetheless, overall the prognosis for SFT 
is better than many adenocarcinomas with 5-year survival 
rates between 59–100% and 10-year survival rates between 
40% to 89% (4,54). In one of the larger reviews of SFT 
with analysis of 110 patients from MD Anderson in 2012, 
the overall 5 and 10-year disease specific survival was 
observed was 89% and 73% respectively (7).
Multiple factors have been associated with survival 
(Table 1). Gold et al. demonstrated recurrent tumors, 
macro- or microscopically positive resection margins, 
tumor size >10 cm, >4 mitoses/10 HPF, increased nuclear 
pleomorphism, increased cellularity and presence of 
malignant component all to be poor prognostic factors (6). 
In another large study by England et al. they identified size 
>10 cm, tumor necrosis or hemorrhage, increased cellularity, 
pleomorphism, and >4 mitoses/10 HPF to be consistent 
with malignant behavior and worse prognosis (11). 
A smaller series published by Witkin et al. found similar 
findings to both Gold and England (12). Demicco et al. 
developed and proposed a risk stratification model to 
classify patients into low, intermediate and high risk based 
on patient age, tumor size and mitotic figures/10 HPF (7). 
Surveillance
Routine follow up is essential for SFT after surgical 
resection (54). Oncologic surveillance provides opportunity 
for early treatment of recurrent or metastatic disease. 
Given the low incidence of SFT, there are not currently 
agreed upon guidelines for surveillance. Many research 
groups have attempted to create risk models in order to 
guide post-operative surveillance with varying results 
(6,7). As stated above, the review from MD Anderson 
displayed that tumors greater than 15 cm in older patients 
(greater than 55) with mitotic figures greater than or 
equal to 4/10 high power fields were at high risk of 
metastasis deserving close surveillance (7). Surveillance 
of each patient should be patient specific dependent on 
tumor location and other patient factors. While many 
oncologic diseases are followed for limited periods of 
times such as 5 years, SFT has been diagnosed in many 
patients later in life potentiating the need for lifetime 
surveillance as recurrence has been noted to occur 
many years after initial diagnosis and treatment (56).
Future perspectives
Given the rarity of SFT and mostly retrospective data from 
small cases series, there is still much progress to be made. 
Although researchers have gained significant understanding 
of the molecular pathways of SFT, the effectiveness of most 
chemotherapies against SFT is relatively poor. Additional 
clinical studies are needed to better elucidate the molecular 
pathways involved with SFT in order to identify more 
Table 1 Tumor features associated with malignant behavior
Study Tumor features
Gold  
et al. (6)
Recurrent tumor
Macro- or microscopically positive resection margin
Size >10 cm
>4 mitoses/10 HPFs
Increased nuclear pleomorphism
Increased cellularity
Presence of malignant components
Demicco 
et al. (7)
Age ≥55 years
Size ≥15 cm
≥4 mitoses/10 HPFs
Tumor necrosis
England  
et al. (11) 
Size >10 cm
Tumor necrosis or hemorrhage
Increased cellularity
Nuclear pleomorphism
>4 mitoses/10 HPFs
Wikin  
et al. (12) 
Size ≥10 cm
Hypercellularity
>1 mitosis/10 HPFs
Tumor necrosis or hemorrhage
HPFs, high power fields. 
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efficient targeted therapy. This will further lead to more 
personalized analysis of each patient’s tumor’s biology 
leading to better ways to assess prognosis and treat each 
individual tumor. In a study, out of Human Pathology in 
2014, researchers evaluated the variations of the NAB2-
STAT6 fusion gene and were able to differentiate which 
mutations were more likely to be aggressive than others (70). 
Further, some researchers have begun analyzing the 
effectiveness of chemotherapy in regard to degree of 
differentiation and aggressiveness of the primary tumor (67). 
Stacchiotti interestingly found that more aggressive SFTs 
seemed more sensitive to cytotoxic chemotherapy (65-67). 
Conclusions
SFTs are a rare slow-growing mesenchymal tumor that has 
been differentiated from other soft tissue tumors over the 
past decades through advances in histology and molecular 
genetics. While surgical resection is the mainstay of 
treatment and provides favorable outcomes for resectable 
disease, radiation and chemotherapy may have potential roles 
in the treatment algorithm. Optimal treatment of advanced 
and metastatic disease is still unclear, but currently involves 
a combination of surgical, radiation, and chemotherapeutic 
strategies under the supervision of a multidisciplinary team. 
Increasing research into various chemotherapy regimens and 
radiation has shown encouraging results, but more research is 
needed for further clinical translation.
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